Skip to content


    DEA Class;  Rx

    Common Brand Names; Lexapro

    • Antidepressants, SSRIs

    Oral selective serotonin reuptake inhibitor (SSRI) antidepressant; an enantiomer of citalopram
    Indicated in adults for major depression and generalized anxiety disorder and pediatric patients 12 and older for depression
    Increased risk of suicidality during treatment initiation in pediatric and young adult patients

    Indicated for acute and maintenance treatment of major depressive disorder (MDD)

    Indicated for acute treatment of generalized anxiety disorder (GAD)

    For the treatment of irritability associated with autistic disorder.
    For the treatment of social phobia (social anxiety disorder).
    For the treatment of panic disorder.

    Hypersensitivity to escitalopram or citalopram


    • Headache (24%)
    • Nausea (15-18%)
    • Insomnia (7-14%)
    • Diarrhea (6-14%)
    • Somnolence (4-13%)
    • Ejaculation disorder (9-12%)
    • Xerostomia (4-9%)
    • Constipation (3-6%)
    • Fatigue (2-8%)
    • Dizziness (4-7%)
    • Libido decrease (3-7%)
    • Anorgasmia (2-6%)
    • Indigestion (2-6%)
    • Sweating increased (4-5%)
    • Rhinitis (5%)
    • Flu-like syndrome (5%)
    • Abnormal dreaming (3%)
    • Neck/shoulder pain (3%)
    • Decreased appetite (3%)
    • Vomiting (3%)
    • Sinusitis (3%)
    • Lethargy (3%)
    • Impotence (3%)
    • Menstrual disorder (1-2%)
    • Flatulence (2%)
    • Toothache (2%)
    • Yawning (2%)
    • Abdominal pain (2%)
    • Weight gain (1%)

    Increased risk of suicidal thoughts and behaviors in adolescents and young adults; monitor all antidepressant-treated patients for any indication for clinical worsening and emergence of suicidal thoughts and behaviors, especially during initial few months of drug therapy

    Conflicting evidence regarding use of SSRIs during pregnancy and increased risk of persistent pulmonary hypertension of the newborn, or PPHN (see Pregnancy)

    In neonates exposed to SNRIs/SSRIs late in third trimester: risk of complications such as feeding difficulties, irritability, and respiratory problems

    Activation of mania/hypomania reported in a small proportion of patients with major affective disorders treated with drugs effective in treatment of major depressive disorder; before initiating, screen for any personal or family history of bipolar disorder, mania, or hypomania

    Risk of mydriasis; may trigger angle closure attack in patients with angle closure glaucoma with anatomically narrow angles without a patent iridectomy

    In a study in normal volunteers, escitalopram10 mg/day did not impair intellectual function or psychomotor performance; because any psychoactive drug may impair judgment, thinking, or motor skills, caution patients about operating hazardous machinery, including automobiles, until they are they know how the drug affects their cognition

    SSRIs/SNRIs increase risk of abnormal bleeding owing to platelet inhibition

    There are no adequate and well-controlled studies in pregnant women; therefore, use during pregnancy only if the potential benefit justifies the potential risk to the fetus

    Escitalopram is excreted in human breast milk


    20 mg/day PO.


    10 mg/day PO.


    20 mg/day PO.


    12 years: 20 mg/day PO.
    6 to 11 years: Safety and efficacy have not been established; however, doses up to 20 mg/day PO have been used for anxiety and pervasive developmental disorders.
    1 to 5 years: Safety and efficacy have not been established.


    Safety and efficacy have not been established.


    Safety and efficacy have not been established.

    Escitalopram oxalate


    • 5mg
    • 10mg
    • 20mg

    oral solution

    • 5mg/5mL